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Abstract
The field of regenerative medicine (RM) has considerable therapeutic
promise that is proving difficult to realize. As a result, governments have
supported the establishment of intermediary agencies to “accelerate”
innovation. This article examines in detail one such agency, the United
Kingdom’s Cell and Gene Therapy Catapult (CGTC). We describe
CGTC’s role as an accelerator agency and its value narrative, which
combines both “health and wealth.” Drawing on the notion of socio-
technical imaginaries, we unpack the tensions within this narrative and its
instantiation as the CGTC cell therapy infrastructure is built and engages
with other agencies, some of which have different priorities and roles to
play within the RM field.
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Introduction
Regenerative medicine (RM) has been defined as that which “replaces or
regenerates human cells, tissue and organs, to restore or establish normal
function” (Mason and Dunnill 2008, 4). This is considered to be revolu-
tionary when compared to conventional treatments based on drugs or
devices, and it is widely claimed that RM will have the potential to provide
curative treatments for a range of illnesses, such as diabetes, heart disease,
and various neurological disorders (Department for Business, Innovation &
Skills 2011). There is, then, considerable high expectation about RM’s
clinical potential (Morrison 2012).
Clinical promise surrounding RM is accompanied by highly optimistic
claims about its economic impact. RM, it is claimed, will become the basis
for a thriving industry that will underpin a high-wealth, knowledge-based
economy. The Japanese government, for example, has named RM as a pillar
of its economic growth strategy (Ogawa 2015), and the promise of eco-
nomic growth was a motivation for the State of California’s “Proposition
71: The Californian Stem Cell Research and Cures Initiative” (Longaker,
Baker, and Greely 2007). In the UK, RM was named by the British gov-
ernment as one of the “eight great technologies” that will drive economic
growth within the UK and which has the potential to become a multibillion
pound industry (Willetts 2013). As with each of the “great” technologies,
RM has been identified as an area in which the UK can excel, but in which
targeted public investment will be needed to convert a strong science base
into a wealth-generating industry. This is part of a broader discourse on
“health and wealth” in the UK involving close alignment of biomedical
researchers, the health-care system, and the commercial sector (Shaw and
Greenhalgh 2008).
At the same time, however, there are concerns that the potential of RM to
deliver curative treatments and generate wealth will be hindered by an array
of innovation challenges (Gardner et al. 2015; Gardner and Webster 2016).
Currently, there are few RM therapies available to patients, which some
commentators argue reflects an incommensurability between the health-
care system and the exigencies of the nascent RM field (Tait 2007; Omidvar
et al. 2014). Specific concerns relate to the instability of live tissues and
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cells, manufacturing scale-up and logistical difficulties, the burden of cur-
rent regulatory arrangements, securing reimbursement (payment), and the
challenge of integrating novel procedures into existing day-to-day health-
care workflows. In several countries, this discourse of concern has
prompted the formation of publicly funded, innovation “accelerator” agen-
cies whose aim is to promote both a faster route to the clinic and a more
rapid valorization of product. These include, for example, the New York
State Stem Cell Science, the Canadian Centre for Commercialization of
Regenerative Medicine, and, most significantly, the California Institute for
Regenerative Medicine, established in 2004 with a budget of USD3 billion
for RM research, infrastructure, and training.
In the UK, various initiatives have been taken that are designed to over-
come the perceived innovation challenges in RM (Department for Business,
Innovation & Skills 2011; Regenerative Medicine Expert Group 2015;
House of Lords Science and Technology Committee 2013; UK Research
Councils 2012). The most significant initiative has been the innovation
accelerator agency, the Cell and Gene Therapy Catapult (CGTC). The
CGTC was established in 2012, and it has been allocated £70 million in
public funds to help support the development of an RM industry in the UK.
Such initiatives raise important questions for the field of science and tech-
nology studies: how do intermediary agencies such as the CGTC
“accelerate” innovation? How do they attempt to build and mobilize mar-
kets and the infrastructure that can support them? And, more importantly,
what tensions might be there in the narrative of health and wealth, which
drives these processes in the UK (and indeed elsewhere)? In this article, we
address these questions by undertaking the first detailed examination of the
role of the CGTC in the field of RM.
Using data from both fieldwork and secondary sources, and by drawing
on Jasanoff and Kim’s (2009) concept of “sociotechnical imaginaries,” we
examine the value assumptions embedded in specific visions and expec-
tations of the RM future and how the CGTC is implicated in this process.
We are especially interested in those practices that are designed to accel-
erate innovation and facilitate the emergence of a wealth-generating RM
industry. As part of this, the CGTC has a key social role in legitimating
particular RM projects and products that it regards as being commercially
promising. We show how the enactment of the sociotechnical imaginary
of the CGTC depends on the play of––and tensions between––distinct
sociotechnical networks (Callon 1999), which then have important impli-
cations for the realization of commercial biovalue (Waldby 2002), such
that some products may “accelerate” toward the market more readily than
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others. Thereby, the realization of the twin virtues of health and wealth is
not so easily achieved: competing values and priorities complicate the
innovation journey.
Intermediary Agencies and the (Accelerated)
Generation of Value
Intermediary agencies in the RM field create diverse forms of value that
serve different purposes and users. A contrast can be made, for example,
between the CGTC and another influential institution in the RM landscape,
the UK Stem Cell Bank (UKSCB). The UKSCB, which has been exten-
sively explored (Stephens, Atkinson, and Glasner 2008, 2013; Stephens,
Lewis, and Atkinson 2013), was established in 2004, and its creation was in
response to a widespread concern at that time about the ethical procurement
of human embryonic stem cells (hESCs). The bank was tasked with miti-
gating such concerns by establishing an ethical repository of hESC lines for
research and clinical purposes. It seeks to do this through managing and
facilitating the ethical sourcing and use of cell lines as either research (i.e.,
for experimental lab-based work) or clinical (i.e., for therapeutic interven-
tion) grade lines. Like the UKSCB, the formation of the CGTC was
prompted by prevalent political concerns of the time, which were more to
do with markets than with ethics. The CGTC was formed in the hope that it
would facilitate the flow of tissues and cells, expertise, and investment that
would be required to ensure that the UK’s “excellent basic science base”
would be translated into useful, commercially successful therapies (Thomp-
son and Foster 2013). Unlike the UKSCB, however, which deals in lines
whose comparability (and therefore value) derives from their being stan-
dardized and ethically procured, the CGTC seeks to create and define the
value of cell lines/therapies by calculating and subsequently creating their
marketability. This requires the construction of future-oriented visions that
are allied to considerable organizational labor and resources through which
a manufacturing platform and related services can be put in place.
Jasanoff and Kim’s (2009) notion of “sociotechnical imaginaries” pro-
vides a useful framework for understanding the role of intermediary inno-
vation agencies such as the CGTC and the UKSCB. Sociotechnical
imaginaries are collectively produced visions of social life that are reflected
in the design of current sociotechnical projects. These visions may be
future-oriented, and they encode particular understandings of what consti-
tutes a “good society” (Jasanoff and Kim 2009, 123). By being enacted in
the present, they also have productive, structuring effects in the present: as
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with promissory expectations more generally (Borup et al. 2006), institu-
tional imaginaries delineate social roles and coordinate alliance-building
activities. Stephens, Atkinson & Glasner (2013), for example, argue that
the UKSCB enacts a particular institutional sociotechnical imaginary. Spe-
cifically, its institutional structure and governance model is designed to
reassure UK publics that its activities are ethical and serve a public good
role. This requires that it be seen as a trustworthy institution, and it entails a
set of activities that validate certain researchers and certain laboratories and
clinics as being ethical producers or users of hESC (and other) lines stored
in the bank. As a result, networks of tissue flow become validated as
“ethical.” It is through such work that a socially legitimated future for stem
cell medicine is proposed (Stephens, Atkinson, and Glasner 2008).
In a similar vein, the CGTC reflects particular sociotechnical imagin-
aries, though they are aligned not with ethics but with notions of health and
wealth, ostensibly twinned national interests combining values associated
with the public (population health) good and the private market. This, in
turn, requires the formation of a durable infrastructure through which such
an imaginary can be framed and mobilized (Callon 1999). The CGTC
infrastructure is based on the sociotechnical imaginary of the “catapult”
model that was originally created in 2010 by the Technology Strategy
Board (now known as Innovate UK), a public agency which reports to the
Department for Business, Energy, and Industrial Strategy. There are cur-
rently nine catapults that have been formed to bring together expertise and
resources in diverse science and technology areas (such as transport, digital
technologies, energy systems, etc.), all of which have been identified as
having the potential to drive––or to catapult––economic growth. They are
described as being nonprofit, business-led centers that connect business
with the UK’s research and academic communities.
The CGTC, established 2012, is based in London and has approximately
a hundred staff. According to its webpage, its stated aim is to
Lead the UK cell therapy industry to create health and wealth from the UK’s
outstanding science foundation and make the UK the most compelling and
logical choice for our international partners. (CTC 2015a)
This emphasis on creating health and wealth in building a new RM indus-
try is reflected in the personnel who comprise senior staff in the CGTC.
The board of directors has six members from the biotech, pharma, and life
sciences industry and two members with academic science backgrounds.
All five members of the management team have a professional
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background in the life-sciences industry, and the advisory group includes
eight representatives from various companies (including AstraZeneca,
GlaxoSmithKline, GE HealthCare, and Johnson & Johnson) and seven
stem cell scientists.
In general terms, the CGTC positions itself as an innovation accelerator,
as expressed in four linked activities that reflect a linear path from upstream
to more applied innovation. First, it aims to facilitate “upstream” innovation
by helping universities to “capture [the] value” of their academic research in
the field. CGTC staff say they have “crisscrossed” the UK, screening uni-
versities for promising RM projects, with the intention of facilitating lin-
kages between academic researchers, university technology transfer
officers, and industry. This has involved identifying the key challenges to
innovation at this upstream stage, one of which is focused on identifying
and managing intellectual property (IP). Hence, the CGTC established an IP
and access scheme “to capture the value of [universities’] novel IP” (Her-
bert 2014, 15). The CGTC also collaborates with academic researchers on
grant applications (in part to help secure additional funding for itself), and it
actively supports RM conferences (CTC 2014b). Second, the CGTC seeks
to support clinical development, clinical trialing, and navigating regulation.
They collaborate with academic and commercial partners to push projects
into the clinical trial phase of development by providing advice on navigat-
ing the trials process and, in some cases, by acting as a clinical trials sponsor
(ensuring that a trial is appropriately funded and managed). Such support is
thought to be especially important for those small companies that dominate
the RM landscape and lack the necessary in-house skills and resources to do
this independently. Third, and closer to more applied processes, the CGTC
supports RM manufacturing and logistics operations, which include clean-
room/laboratory space for rental by users and in which cell and tissue
manufacturing processes can be trialed according to legally defined quality
standards. Finally, the CGTC’s expertise in finance, health-care economics,
and business models is intended to assist partners in formulating an RM
product development pathway that takes into account assumptions about
target markets and anticipated innovation challenges in order to build RM
businesses “with investable propositions” (CTC 2014b, 7). More broadly,
the CGTC plays something of a lobbying role for those working within the
field of RM, pushing for the regulatory and policy adjustments that are
believed to facilitate innovation in the field. Overall, then, as an accelerator
agency, the CGTC illustrates what Salter and Faulkner (2011, 1-2) refer to
as the established policy orthodoxy in “competition” states such as the UK;
an orthodoxy in which the state––through agencies like the Catapult––aims
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to “foster the conditions necessary for innovation,” “stimulating a dynamic”
that enables a field eventually to become self-sustaining, rather than (as in
the era of corporatist industrial strategy) directly sponsoring particular firms
or technology sectors.
In these ways, the CGTC acts to steer what might otherwise be dis-
persed, heterogeneous, and uncoordinated research and clinical activity
into particular paths of RM commercialization, aimed at generating mar-
ket value. The CGTC can be seen as the materialization and institutiona-
lization of a set of promissory expectations (Borup et al. 2006) about the
clinical and economic value of biological material. These expectations are
combined with broader assumptions about the role of the private and
public sectors in innovation and wealth creation, a neoliberal agenda that
assigns to knowledge and health a market value and sees the “public good”
as coinciding with market commercialization. Together, these expecta-
tions and assumptions form a sociotechnical imaginary grounded in the
notion of accelerated innovation. As we shall see, however, biological
material––the cell line, for example––is immersed in various
“entanglements” that encompass a range of other actors. Such entangle-
ments are indicative of the tensions that arise within the “competition
state” (Salter 2009), in which a diversity of actors, expertise, and knowl-
edge are mobilized in an attempt to generate health and wealth. We
explore these in the fourth section.
Method
We draw upon data that have been collected as part of a larger social
science project funded by the Economic and Social Research Council,
exploring the social dynamics of innovation within the field of RM. The
project involved over eighty interviews with stem cell scientists, clini-
cians developing RM therapies, regulators, patient association represen-
tatives, industry representatives, health economists, and public servants
working within the health-care system. Elsewhere, we have published
work relating to the specific factors shaping the adoption of RM in distinct
clinical contexts (Gardner and Webster 2016; Gardner et al. 2017). In this
article, we draw specifically on a subset of this much larger data set where
respondents reflect upon their engagement with the CGTC. Several of
these respondents are professionally associated with the CGTC, while
others have engaged with the CGTC in seeking advice or assistance. This
article has also been informed by our field notes of several RM-industry
conferences and workshops that we attended, and it draws upon various
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forms of secondary data. These include CGTC webpages, annual reports
and other official publications, and the publicly available reports and
minutes of other agencies in which the CGTC is mentioned and that
provide useful background on the CGTC itself. Ethics approval for the
data collection activities was obtained from the relevant institutional
ethics committees, and informed consent was obtained from all partici-
pants. In the next section, we discuss two of the central processes associ-
ated with the accelerated generation of products that are shaped by the
health and wealth social imaginary: the selection and positioning or con-
figuring of potential products and the endeavors directed at purifying and
scaling them up for the market. We then examine how both processes
come into tension with other players and values at work in the field.
Findings
Configuring Products for Health and Wealth
A key role played by the CGTC is its direct engagement with firms (mostly
but not exclusively UK-based) to help identify those products that are more
likely to be effectively configured and positioned for an RM market. These
are products that are often at an early stage of development. In terms of the
trials process, they are typically at the preclinical phase, or phase I or II, and
so they are at a point when a potential product moves toward early efficacy
tests and, depending on the results of such tests, manufacturing scale-up. In
some cases, the Catapult will enter into collaborative “core” partnerships
with smaller companies and organizations with “medium-” or “high-risk”
projects (CTC 2015a), which may last several years. Currently, the CGTC is
involved in over forty projects with companies or organizations, and it is
currently sponsoring two RM clinical trials. In this section, we focus on
those activities aimed at early stage product development. We draw on
secondary data and interviews with individuals who have been involved
in projects receiving CGTC assistance, and we show how these activities
attempt to position and configure a prospective RM product for an envi-
saged RM market.
The business development and market access activities of the CGTC
bring together and focus its broad expertise on a specific company or
organization with a novel and potentially promising technology. The orga-
nization and the technology are subject to detailed scrutiny and assessment
of its perceived commercial value. Below, a scientist working in immu-
notherapy describes this process:
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So the [RM work] that we’ve been doing . . . [the CGTC] actually invested a
lot of time and effort in preparing a report on the strengths and weaknesses of
the technology, of how to drive it forward, of what the gap analysis was. Our
intellectual property and its strengths and weaknesses there. The market that
there would be. So they actually put a lot of effort into producing a very
detailed report on our technology, which has been very helpful . . . the purpose
of the report that they prepared for us was to identify what the needs were in
translating it to the clinic. So because of that report we have a much better
idea of the way forward and we’ve been trying to raise the money to actually
take it forward ever since. (Scientist 1)
Several of our respondents reported similar engagement with the CGTC,
and as the quote illustrates, this engagement entails foregrounding and
assessing particular parameters through which value is to be configured.
These relate to determining what is described as the “value proposition” of
the technology, and hence the associated potential market of the technol-
ogy, the possible pathway for further developing the technology, and an
assessment of its immediate and longer-term IP value. These parameters, of
course, reflect the assumptions and professional background of the CGTC
staff, and in foregrounding these (and so discounting others), the CGTC acts
to produce a vision of the future centered on commercialization and wealth
creation. In effect, this sociotechnical imaginary becomes––via its institu-
tionalization in the CGTC––a structuring principle for the production of
future-oriented visions for specific RM projects, thus steering mechanisms
that overtime are likely to foster a product’s path dependency as it moves
toward the market. A core feature of these future-oriented visions is the
delineation of the anticipated use of the technology, that is, how it will
address a particular clinical or research need in an anticipated future. In
this way, we see the narrative of “RM as health-generating industry” com-
ing into prominence. Companies and organizations will have some idea of
the prospective clinical use value and the “pathway to the clinic” of their
technology prior to their engagement with the CGTC, but the activities of
the CGTC can be seen as adjusting, further delineating, and reifying par-
ticular visions of that future.
As the sociology of expectations literature has illustrated, promissory
visions of the future have performative effects 2000 (Brown, Rappert, and
Webster 2000; Borup et al. 2006). This is apparent in the way in which a
CGTC-mandated prospective clinical use value adds reputational authority
to the emerging product or therapy. As the respondents below note, for
example, the involvement of the CGTC provided their projects with
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credibility, which in turn garnered financial assets that could be deployed
early in their work:
So the Cell [and Gene] Therapy Catapult were important to us . . . they gave
[our company] and the management team I guess a vote of confidence by
putting their support behind us . . . now we have the backing of the Cell [and
Gene] Therapy Catapult who were an organization set up essentially by the
TSB and the government to promote and accelerate regenerative medicine in
the UK and support companies like us. So that was a huge boost for us and a
tick in the credibility box. It enabled us to get the [agency] grant at that time.
(CEO—small company)
They have also supported various grant applications that we’ve submitted
with letters of support saying how they, you know, think this is a ground
breaking technology and so on. (Scientist 1)
As the extracts show, this credibility can be leveraged to secure additional
funding, enabling the project to progress further along the envisaged trans-
lational pipeline. Importantly, as the CEO’s comment above indicates, the
CGTC’s social role as “validator” depends on its reputation. Due to its
association with the Technology Strategy Board (TSB), and due to the
perceived expertise of its personnel, the CGTC appears to have been, at
least among some stakeholders, endowed with the authority to judge the
commercial viability of RM projects. Hence, the CGTC adds authoritative
weight to prospective clinical values and legitimates particular visions of
the future, which thus have a stronger performative impact in the present.
Purifying Products: Disentanglement and Framing
Commodities and the markets within which they are exchanged have to be
actively created and maintained by different agents. They require socio-
technical networks that facilitate types of flows of goods and services.
These networks, Callon (1999) has suggested, play a key role in disentan-
gling and framing entities so that the latter are enacted as commodities;
network agents seek to obscure, elide, or sever material and semiotic asso-
ciations (disentanglement) that could hinder their extraction and exchange;
and they establish and foreground (frame) other material and semiotic
associations that delineate their relative value, enable their mobility, and
thereby promote their consumption. As we have seen in the preceding
section, the CGTC is one agent within an emerging RM network that aims
to do this. This is apparent, for example, in its role in establishing the IP for
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a novel therapy or product: IP claims (e.g., through patent filing) serve to set
out the specific knowledge claims and supporting methods on which they
depend, discrete, or disentangled from the current “state of the art” that
thereby demonstrates their novelty.
The delineation and validation of the possible economic and clinical
value of a product can be seen as part of this disentangling and framing
process. However, there are other entanglements with various degrees of
obduracy that the CGTC has to consider. A major role of the CGTC is to
facilitate the production of the infrastructure that will enable the industrial
scale production of cell and tissue-based products (CTC 2015b). A chal-
lenge in this regard for any developer of RM products is the material–
physical entanglement of biological material. Cells and tissues are immen-
sely sensitive to their surrounding niche, small changes that can drastically
affect their clinical quality, potency, and safety. Cell- and tissue-based RM
technologies must, according to the US Food and Drug Administration
(FDA) and the European Medicines Agency (EMA) regulatory frameworks,
be manufactured in clean-room facilities that meet strict Good Manufac-
turing Practice (GMP) standards. Cells and tissues need to be carefully
procured, expanded, and assayed to ensure they meet quality standards
and then carefully distributed to the point of care. These processes gen-
erally involve the physical disentanglement of cells and tissues from their
original locus (bone marrow aspirate, adipose tissue, etc.) to secure their
mobility, the maintenance of some degree of cell-niche physical entan-
glement necessary to keep cells viable, the introduction of new physical
entanglements (such as growth factors, adhesive surfaces) to encourage
expansion and differentiation of cells or the selection of desired cell
types, and the shielding from unwanted entanglements (contaminants).
Currently, these processes often involve labor-intensive “open systems”
whose activities are conducted by staff with the appropriate expertise. In
order to produce the larger quantity of cells that would be needed for
phase III trials or commercial use, less-labor intensive, “closed systems”
need to be developed (using bespoke bioreactors, for example), in which
some processing steps are automated. Some automated devices have been
developed for forms of cell processing, but the use of these needs to be
validated by regulators (see Addison 2017). Most importantly, developers
must ensure the stability and purity of the product such that it does not
carry any “adventitious agents” (i.e., potential biological material such as
prions, bacteria, viruses, etc.) that would bring harm to a patient. The
costs—especially for developing closed processing systems that can
achieve such levels of purification and stability of cells and for
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maintaining a GMP facility––are high and are said to represent a major
translational challenge in RM. Additionally, the existing GMP facilities
within which these disentanglement/entanglement processes take place
are small and cater to the production of small-scale production of RM
technologies needed in phases I and II clinical trials (which involve small
numbers of participants). They lack the capacity, then, to produce the vast
quantities of cells and tissues that would be needed for larger phase III
trials or for commercial use (HoL 2013).
These sociotechnical demands––found across the RM field––pose
considerable challenges to the CGTC’s role as an accelerator agency and
its drive toward health and wealth. The Catapult has sought to build
internal expertise in technology transfer, scale-up, supply chain manage-
ment, logistics, and GMP. In its collaborations with commercial/aca-
demic organizations, the Catapult aims to develop and improve
production and logistics processes, and it provides access to their existing
manufacturing space to test new systems (CTC 2015b). As a demonstra-
tion of the power of the sociotechnical imaginary embodied in the CTGC,
it has begun construction of a 5,000 m2 publicly funded manufacturing
facility (at a cost of £55 million). The CGTC believes that the facility will
provide adequate capacity for large-scale production of cell and gene
therapies (CTC 2014a) as the need for such facilities grows in the envi-
saged future.
The facility can be seen as an attempt to create the infrastructure that will
support the large-scale disentanglement/entanglement that is necessary for
the commercialized flow of live tissues from places of production to places
of consumption. It is a material manifestation of promissory expectations
and reflects particular understandings about relationships and activities that
are needed to enable translation of RM technologies to the clinic. As the
CGTC user requirements brief states (CTC 2014c), the facility is being
designed so that it enables:
a) current UK clinical manufacturing programs to access the space as demand
for scale increases with clinical and commercial maturity; b) product devel-
oper companies to produce their own products to help ensure maximum value
is retained within the company; c) global companies with more clinically
advanced products to locate in the UK to supply EU and, where possible,
global markets. (p. 5)
The facility is currently under construction in Stevenage with easy access to
London Heathrow airport, the only airport in the UK that, according to the
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CGTC, has sufficient connectivity to enable the quick transport of RM
products to clinics throughout the world (CTC 2014c). Its proximity to
London will also ensure access to highly trained staff, and it is being con-
structed within a life sciences park that has existing infrastructure to ensure
ample power supply, waste disposal, and other amenities. The facility will
be GMP licensed, and it will be composed of self-contained modules (clean
rooms) that can be hired by companies that would otherwise lack the
resources to produce their own large-scale facilities. The modules are being
designed as spaces that are both rigid and flexible: rigid in certain aspects to
maintain strict GMP standards (such as carefully controlled airflow, and
segregated flows of wastes, input materials, and so on) and highly flexible
in other aspects, so that individual companies can adjust the space as needed
depending on the required production processes that, it is envisaged, will
change and improve over time. The facility is also being designed to ensure
several companies can use the facility at once while protecting commer-
cially sensitive information and practices: personnel access and movement
around the facility is to be carefully controlled, and the physical partitioning
between modules will enable entanglement/disentanglement processes and
know-how to be kept confidential. The first phase of the construction pro-
cess, which includes the construction of six modules, is expected to be
completed in 2017. The facility represents an attempt to establish the con-
ditions for the large-scale, commercial derivation of biovalue––the “yield
of vitality produced by the biotechnical reformulation of living processes”
(Waldby 2002)––that can thus be directed toward the realization of health
and wealth.
Beyond the domain of the CGTC itself, at a wider international level,
several RM products have moved sufficiently along the translational path-
way to obtain regulatory authorization. Indeed, within the EU, eight RM
products have been deemed safe and effective via the Advanced Therapy
Medicine Product framework and can now be marketed by their manufac-
turers. Yet, none of these products has been integrated in health-care sys-
tems in a widespread way: the biovalue of RM products (pertaining to both
clinical and commercial value) remains largely “promissory” in nature. In
South Korea, for example, sixteen RM therapies have received regulatory
approval, yet none of these is exported or reimbursed outside of the country
(Faulkner 2016). In the following section, we explore why this is the case by
drawing attention to some of the other present-day entanglements that
complicate the activities of the CGTC and translation activities in RMmore
generally, and which make the process of acceleration––and the realization
of a sociotechnical imaginary––much more problematic.
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Entanglements and Values in Tension
As noted above, the innovation-accelerating activities of agencies such as
the CGTC are complicated by other actors that populate the RM field. In
effect, these actors are implicated in entangling biological material in var-
ious ways, some of which enact values or visions of the future that are
potentially in tension with the consolidation of clinical and market value.
These derive from and are mobilized by different networks that cut across
the CGTC’s activities. We describe below some of the problematizing––
and sometimes countervailing––values that are at work and then give some
examples of the impact that this can have on prospective products. Our
subsequent and concluding discussion will reflect on which of these pro-
cesses is most likely to pose problems for the realization of the CGTC’s
sociotechnical imaginary.
Some forms of entanglement relate to the biological material used in
upstream innovation activities, such as the acquisition of, and investment
in, cell lines. For example, tissues derived from human embryonic mate-
rial are entangled in morally charged understandings that have shaped the
EU legal landscape for RM. One important issue relates to those legal
instruments that permit private ownership and exclusive rights to partic-
ular types of “inventions” (thus enabling maximum market value to be
retained within a company). These various legal instruments are them-
selves a reflection of expectations about how innovation can and should be
done and where rewards may accrue (Sandor and Varju 2013). Within the
EU, a key legal instrument in the field of RM is the so-called Biopatent
Directive,1 which permits private ownership of particular types of inven-
tions derived from biological entities, but not inventions derived from
hESC. This latter exclusion reflects the perceptions of a specific set of
actors within the EU (particularly within the European Parliament) that
the embryo is a morally privileged entity due to its potential to become a
“human.” The directive, then, reflects and enacts a form of value, which
could be called “moral value,” and which is in tension with commercia-
lization. It has been the subject of some criticism (Gilbert and Lees 2012),
as commentators have felt that it would discourage commercial invest-
ment within the EU and companies would direct their attention to juris-
dictions such as the United States, where hESC-derived technologies can
be patented. While some companies have persisted in developing hESC-
derived technologies within the EU, others have deliberately avoided the
hESC route to the market. This was the initial strategy of UK-based
ReNeuron, which used fetal brain tissue to develop its ReN001 stem cell
14 Science, Technology, & Human Values XX(X)
therapy for the treatment of strokes, patenting the expansion and process-
ing technologies used to produce them.
Another related entanglement that may complicate the commerciali-
zation of biological material relates to the debate concerning public good
versus private ownership. Some publicly funded tissue banks in the RM
field, such as the UKSCB, have procured tissue deposits on the under-
standing that they would be public goods––that is, that they would be
made available as an international resource to any researchers who meet
specific ethical criteria. In effect, such banking practices enact tissues as
having a public good value due to their capacity to generate knowledge,
and so priority is given to research that will use, test, and thus further
characterize banked cell lines. Researchers and companies who obtain
cells from such banks cannot claim exclusive use for them, and, more
significantly, those who deposit lines in the bank must make them avail-
able to third parties. The bank grants nonexclusive, royalty-free research
licenses for cell lines, without the right to sublicense. Commentators
have suggested that the commercial sector will be reluctant to invest
in cell-based research and technologies because they cannot guarantee
exclusive access to the lines they have deposited. As an interviewee
stated:
They’d invest in the acquisition of stem cell lines, only for others to benefit
from those lines. (Interview, IP consultant)
Other forms of entanglement relate to “downstream” translation activities,
an influential example of which is the economic assessments (Health
Technology Appraisals or HTAs) of RM technologies carried out by
authorities such as UK’s National Institute for Health and Care Excel-
lence (NICE) when deciding whether to adopt the technology within a
health-care system. An HTA is a means of ensuring that only cost-
effective technologies will be adopted, that is, only those technologies
whose clinical effectiveness justifies their cost (RM technologies may be
high cost due to their complex manufacturing processes). Manufacturers
must submit a range of data that can be used to calculate both the antici-
pated implementation and day-to-day cost of the technology if it were to
be adopted, and the anticipated clinical and social benefits to the patient.
In effect, various points of reference are used to forecast a future for the
technology; it becomes entangled within future-oriented understanding as
being cost-effective or not (or as being “unable to appraise” due to
insufficient data). Given the gatekeeping role of HTA agencies, these
Gardner and Webster 15
entanglements can have a major impact on the success of an innovation
(Regenerative Medicine Expert Group 2015).
A good example of this is ChondroCelect, an autologous-
chondrocyte-based product developed by the Belgium company,
TiGenix, for treating cartilage defects in the knee. In 2009, ChondroCe-
lect was the first RM product to receive marketing authorization via the
European Medicine Agency’s Committee for Advanced Therapies; exist-
ing clinical data, the committee declared, demonstrated that the product
was clinically effective and had an acceptable safety profile. Yet Chon-
droCelect failed to be widely adopted within EU health-care systems,
largely due to uncertainties about its cost-effectiveness. In the UK, a cost
assessment conducted by NICE highlighted the limitations in existing
data, particularly relating to longer term clinical benefit, and thus con-
cluded that cost-effectiveness could not yet be demonstrated. It was not,
then, recommended for routine use in the UK Health-care system. Sim-
ilar responses from other national HTA bodies eventually led TiGenix to
declare that the ChondroCelect was not commercially feasible, and it
thus requested that marketing authorization be withdrawn. In this regard,
ChondroCelect illustrates what appears to be a major challenge in the
commercialization of RM.
The commercial (un)feasibility of a product does not necessarily mean
development will come to a grinding halt, however: investors may use their
access to financial resources to drive a product in a different direction, with
the longer-term aim of securing higher prices on the market and so a major
return on their investment (Roy and King 2016; Birch 2016). A good example
of this is Prochymal, a mesenchymal stem cell-based, immunomodulatory
product. The product was developed by Osiris and it underwent clinical trials
for several indications with mostly disappointing results. Although approved
in some jurisdictions for the treatment of graft-versus-host disease, the small
patient population with this indication suggested it would have limited com-
mercial value. The product was, nevertheless, purchased from Osiris by the
Australian company Mesoblast at a cost of USD50 million and is now under-
going clinical trials for Crohn’s disease (Waltz 2013). A more recent (2015)
additional investment of USD45 million has been made by Celgene, on the
assumption that they can secure a broader license to treat a number of more
common related conditions.
Both the ChondroCelect and Prochymal stories show how the
commercialization of RM can take different directions with different
outcomes depending on the involvement of clinical, regulatory, and
financial actors.
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Discussion: Value Tensions across Networks
What we have shown in this article is that a strong sociotechnical imaginary
of health and wealth in the UK has been institutionalized within the CGTC,
and it is reflected in the way in which the Catapult attempts to build
momentum around and steer the creation of prospective novel RM products.
This involves a range of activities that we have described as entailing the
disentangling and framing of prospective products so that they are endowed
with specific futures that promise clinical utility, while meeting the inter-
linked challenges of regulatory approval and scale-up. We have also seen
how the envisaging and attempted realization of this biovalue comes into
tension with a number of competing narratives––other entanglements––
such as debates relating to the patenting of biological material, the fostering
of public good within UK research infrastructure through the UKSCB, and
cost assessment analyses that can pose major problems for CGTC and
private company plans relating to reimbursement in the clinical market.
The concept of sociotechnical imaginaries is useful in helping us to see
how some narratives emerge in the play of these entanglements, and how
some come into conflict, and so how certain futures are enabled and others
not. We think that this concept can be given further utility by linking it to
Callon’s (1994) discussion of networks and markets––specifically, the way
in which the latter is performed and brought into being by the former. The
tensions we describe above illustrate how sociotechnical networks can be
aligned or misaligned to varying degrees.
Callon’s discussion of the distinction between “public” and “private”
goods is important here. The discourse of health and wealth suggests a
complementary alignment between practices that serve the public health
of the community on the one hand, and private commercial interests of
industry on the other hand. Callon stresses, however, that we should refrain
from positing an a priori distinction between public and private; rather, we
should see public goods and “private goods” and the distinctions between
them as being performed––or enacted––by often complex networks of
actors. The value tensions we describe above reflect these potentially con-
flicting networks. For Callon, the most important matter of concern is
whether networks enable the circulation and socialization of knowledge,
fostering accessibility to a wide range of users.
We have seen that one of the principal objectives of the CGTC is to help
accelerate the passage of prospective products to the market. As this is
undertaken, countervailing processes come into play that reveal the tensions
between public and private actors and the difficulties faced by the CGTC as
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an intermediary agency that attempts to create bridges between the two. The
various entanglements discussed above, related to patenting and the roles of
the UKSCB and NICE, are points at which the closed/open character of
forms of knowledge come into play––patenting as a form of closure, the
bank as a medium for open access, and NICE as gatekeeper––closing or
opening paths to the market according to comparative cost–benefit model-
ing. Of these three, the Catapult and its partners are most likely to be able to
negotiate the value terrain of patenting and cost–benefit analysis since in
both domains the task is to position knowledge claims such that they can be
seen as being distinct from and adding value to the state of the art. More-
over, the Catapult and NICE may become more aligned. NICE has recently
moved toward modes of assessment intended to facilitate innovation, such
as “progressive value assessment” and “productive risk sharing,” thus
reflecting a perspective that is more in line with the CGTC’s “imaginary,”
at least in broad terms. The more difficult task relates to how to engage with
the sociotechnical imaginary of the UKSCB, which is based on providing
access to thoroughly characterized cell lines checked for quality and safety.
This characterization and checking enables, rather than constrains, access to
and movement of quality-assured lines in a way that maximizes the utility
of lines as a public good resource. In contrast, the free exchange of cell lines
among researchers (i.e., without mediation by a bank) is known to have
resulted in millions of dollars and euros wasted on research due to lack of
quality assurance (e.g., lines may not be properly authenticated or cross-
contamination occurs) and the duplication of effort (Geraghty et al. 2014).
In terms of Callon’s argument, the values enacted by the UKSCB foster not
an unfettered circulation of lines but one anchored in quality assurance.
How the CGTC addresses this question now and in the future is an espe-
cially important challenge to its sociotechnical imaginary, since, while
acknowledging that the quality of lines is of great importance, and one that
depends on researchers being able to access and test lines as third parties,
the parallel weight it gives to the narrative of “wealth” recognizes the
importance that firms give to exclusivity in regard to the use of the lines
they have developed (Holm 2015).
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Note
1. Directive 98/44/EC of the European Parliament and of the Council of July 6,
1998, on the legal protection of biotechnological inventions.
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